Analyst consensus rating
Xeris Biopharma Holdings Analyst Rating: Strong Buy
Direct answer
Xeris Biopharma Holdings's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.29.
Forecast evidence checked September 12, 2026.
Get free Xeris Biopharma Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.45
- Average price target
- $12.29
- High price target
- $18.00
- Low price target
- $8.00
- Low target gap
- +7.4%
- Target upside
- +64.9%
- High target gap
- +141.6%
- Target range width
- 134.2%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- September 12, 2026
- Valid through
- September 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Xeris Biopharma Holdings?
Xeris Biopharma Holdings has a verified Strong Buy consensus. The same dataset has an average price target of $12.29.
How far are Xeris Biopharma Holdings's low and high targets from the recorded price?
The low target implies +7.4%, while the high target implies +141.6%.
How many analysts are included in Xeris Biopharma Holdings's consensus?
The verified consensus includes 7 analysts.
How is Xeris Biopharma Holdings's target upside or downside calculated?
The average target of $12.29 is divided by the recorded price of $7.45, then one is subtracted to produce +64.9%. This does not guarantee a future return.
When was Xeris Biopharma Holdings's analyst forecast verified?
The data was verified on 2026-09-12. The dataset is valid through 2026-09-19.